Spero Therapeutics, Inc. (SPRO)

PriceLoading quote

Financial charts

Revenue

Net income

Free cash flow

Total cash / debt

CashTotal debt

Financial statements

11 annual periodsNewest to oldest
20252024202320222021202020192018201720162015
Revenue$12.6M$371,000$933,000$2.5M$3.1M$258,000$4.7M$4.0M$2.0M$335,000
Research & development$38.5M$96.8M$51.4M$47.6M$64.5M$67.0M$65.8M$33.9M$32.9M$26.3M$11.1M
Operating expenses$60.5M$121.3M$82.3M$95.7M$106.2M$88.4M$81.4M$46.8M$43.7M$33.6M$13.3M
Operating income$6.3M−$73.4M$21.5M−$42.2M−$88.0M−$79.1M−$63.2M−$42.8M−$41.7M−$33.2M−$13.3M
EBITDAderived$6.3M−$73.4M$21.8M−$41.3M−$87.3M−$78.4M−$62.5M−$42.4M−$41.4M−$32.9M−$13.3M
Net income$8.6M−$68.6M$22.8M−$46.4M−$89.8M−$78.3M−$60.9M−$41.7M−$38.7M−$25.5M−$10.2M
Basic EPSper diluted share$0.15-$1.27$0.43-$1.23-$2.91-$3.52-$3.35-$2.60-$17.82-$95.87-$53.11
Diluted EPSper diluted share$0.15-$1.27$0.43-$1.23-$2.91-$3.52-$3.35-$2.60-$17.82-$95.87-$53.11

Insider buys & sells

Jul 1, 2024Jun 30, 2026
Buys0$0.00 disclosed value
Sells (SEC code S)27$914.1K disclosed value
27 recent transactions
TransactionInsiderTypeSharesPriceValueOwned after
May 4, 2026Form 4Rajavelu EstherSee RemarksSellCommon Stock25.2K$2.51$63.4K986.9K
Feb 6, 2026Form 4Rajavelu EstherSee RemarksSellCommon Stock50.8K$2.36$119.9K1.01M
Feb 6, 2026Form 4Rajavelu EstherSee RemarksSellCommon Stock37.1K$2.36$87.6K1.06M
Feb 6, 2026Form 4Keutzer TimothyChief Operating OfficerSellCommon Stock18.7K$2.36$44.0K742.5K
Feb 4, 2026Form 4Keutzer TimothyChief Operating OfficerSellCommon Stock3.5K$2.24$7.8K761.2K